The Cooper Companies Announces Third Quarter 2011 Results
The Cooper Companies Announces Third Quarter 2011 Results
-
Revenue increased 19% year-over-year to
$351.4 million .CooperVision (CVI) revenue up 20% to$298.3 million andCooperSurgical (CSI) revenue up 14% to$53.1 million . -
GAAP earnings per share (EPS)
78 cents , down8 cents from last year's third quarter. -
Non-GAAP EPS
$1.15 , up24 cents from last year's third quarter. See "Reconciliation of Non-GAAP EPS to GAAP EPS" below. -
Free cash flow
$68.3 million . Total debt decreased$108.0 million to$445.2 million .
Commenting on the results,
Third Quarter GAAP Operating Highlights
-
Revenue
$351.4 million , 19% above third quarter 2010, 12% in constant currency. -
Gross margin 58% compared with 60% in last year's third quarter. The decrease was the result of a
$14.2 million reserve for inventory and return provisions related to theAugust 19, 2011 voluntary recall of certain lots of Avaira® Toric contact lenses. Excluding this reserve, gross margin in the third quarter 2011 would have been 62%. -
Operating margin 13% compared with 17% in last year's third quarter. The decrease was the result of the aforementioned Avaira Toric voluntary recall and the reversal of a
$6.1 million one-time gain on settlement of a preexisting relationship related to the acquisition of certain assets from Asahikasei Aime. Excluding this reserve and the reversal of the one-time gain on settlement, operating margin in the third quarter 2011 would have been 19%. -
Depreciation and amortization expense
$25.4 million . -
Interest expense
$3.2 million compared with$8.7 million in last year's third quarter. Interest expense decreased as a result of lower interest rates and lower average debt. -
Cash provided by operations
$87.4 million and capital expenditures$19.1 million resulted in free cash flow of$68.3 million . -
Total debt decreased
$108.0 million to$445.2 million .
Third Quarter CooperVision (CVI) GAAP Operating Highlights
-
Revenue
$298.3 million , up 20% from last year's third quarter, 11% in constant currency. - Revenue by category:
Constant Currency | ||||
(In millions) | % of CVI Revenue | %chg | %chg | |
3Q11 | 3Q11 | y/y | y/y | |
Toric | $ 88.7 | 30% | 17% | 9% |
Multifocal | 19.7 | 6% | 7% | 1% |
Single-use sphere | 64.6 | 22% | 21% | 9% |
Non single-use sphere, other | 125.3 | 42% | 24% | 16% |
Total | $ 298.3 | 100% | 20% | 11% |
- Revenue by geography:
Constant Currency | ||||
(In millions) | % of CVI Revenue | %chg | %chg | |
3Q11 | 3Q11 | y/y | y/y | |
Americas | $ 119.9 | 40% | 7% | 6% |
EMEA | 112.4 | 38% | 25% | 11% |
Asia Pacific | 66.0 | 22% | 40% | 24% |
Total | $ 298.3 | 100% | 20% | 11% |
- Selected revenue by material:
Constant Currency | ||||
(In millions) | % of CVI Revenue | %chg | %chg | |
3Q11 | 3Q11 | y/y | y/y | |
Proclear® | $ 80.7 | 27% | 14% | 5% |
Silicone hydrogel | $ 91.9 | 31% | 56% | 47% |
-
Gross margin 56% compared with 58% in last year's third quarter. The decrease was a result of a reserve for inventory and return provisions related to the
August 19, 2011 voluntary recall of certain lots of Avaira Toric contact lenses. Excluding this reserve, gross margin in the third quarter 2011 would have been 61%.
Third Quarter CooperSurgical (CSI) GAAP Operating Highlights
-
Revenue
$53.1 million , up 14% from last year's third quarter, up 12% excluding acquisitions. - Revenue by category:
(In millions) | % of CSI Revenue | %chg | |
3Q11 | 3Q11 | y/y | |
Office, other | $ 28.9 | 54% | 5% |
Surgical procedures | 20.4 | 39% | 29% |
Fertility | 3.8 | 7% | 12% |
Total | $ 53.1 | 100% | 14% |
- Gross margin 65% compared with 66% in last year's third quarter.
2011 Guidance
The Company amends its full-year fiscal 2011 guidance and provides fiscal fourth quarter guidance. Guidance is summarized as follows:
FY11 Guidance | FY11 Guidance | F4Q11 Guidance | |
Old | New | New | |
Revenues (In millions) | |||
Total | $1,280 - $1,300 | $1,320 - $1,335 | $350 - $365 |
CVI | $1,080 - $1,095 | $1,117 - $1,127 | $300 - $310 |
CSI | $200 - $205 | $203 - $208 | $50 - $55 |
EPS | |||
GAAP | $3.90 - $4.05 | $3.67 - $3.72 | $1.21 - $1.26 |
Non-GAAP* | $4.00 - $4.15 | $4.20 - $4.25 | $1.19 - $1.24 |
Free Cash Flow (In millions) | $190 - $210 | $200 - $220 | $46 - $66 |
* Excludes the impact of the 2009 CVI manufacturing restructuring plan, items related to acquisitions, costs related to the redemption of our senior notes and the reserve for inventory and return provisions related to the
Reconciliation of Non-GAAP EPS to GAAP EPS
To supplement our financial results and guidance presented on a GAAP basis, we use non-GAAP measures that we believe are helpful in understanding our results. The non-GAAP measures exclude inventory and return provisions related to the
Non-GAAP net income and diluted EPS for the fiscal third quarter of 2011 excludes
In the fiscal third quarter of 2011, we recognized a
We also report revenue growth using the non-GAAP financial measure of constant currency revenue. Management presents and refers to constant currency information so that revenue results may be evaluated excluding the effect of foreign currency rate fluctuations. To present this information, current period revenue for entities reporting in currencies other than
Three Months Ended July 31, | |||
2011 GAAP | Adjustments | 2011 Non-GAAP | |
Operating income | $ 45,887 | $ 20,261 | $ 66,148 |
Income before income taxes | $ 43,056 | $ 20,261 | $ 63,317 |
Provision for income taxes | $ 4,919 | $ 2,191 | $ 7,110 |
Net income | $ 38,137 | $ 18,070 | $ 56,207 |
Diluted EPS | $ 0.78 | $ 0.37 | $ 1.15 |
Fiscal 2011 EPS Guidance | |||
2011 GAAP | Adjustments | 2011 Non-GAAP | |
Diluted EPS | $3.67 - $3.72 | $0.53 | $4.20 - $4.25 |
Conference Call and Webcast
The Company will host a conference call today at
About
Forward-Looking Statements
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements which are other than statements of historical fact, including all statements regarding anticipated growth in our revenue, expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like "believes," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties.
Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political and economic conditions due to the current global economic downturn, including the impact of continuing uncertainty and instability of
We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES | ||
Consolidated Condensed Balance Sheets | ||
(In thousands) | ||
(Unaudited) | ||
July 31, | October 31, | |
2011 | 2010 | |
ASSETS | ||
Current assets: | ||
Cash and cash equivalents | $7,872 | $3,573 |
Trade receivables, net | 218,416 | 197,490 |
Inventories | 243,370 | 227,902 |
Deferred tax assets | 33,061 | 28,828 |
Other current assets | 40,917 | 33,547 |
Total current assets | 543,636 | 491,340 |
Property, plant and equipment, net | 601,094 | 593,887 |
Goodwill | 1,270,300 | 1,261,976 |
Other intangibles, net | 125,840 | 114,177 |
Deferred tax assets | 27,208 | 23,072 |
Other assets | 47,256 | 40,566 |
$2,615,334 | $2,525,018 | |
LIABILITIES AND STOCKHOLDERS' EQUITY | ||
Current liabilities: | ||
Short-term debt | $38,735 | $19,159 |
Other current liabilities | 198,958 | 180,361 |
Total current liabilities | 237,693 | 199,520 |
Long-term debt | 406,485 | 591,977 |
Other liabilities | 64,514 | 46,543 |
Deferred tax liabilities | 18,964 | 20,202 |
Total liabilities | 727,656 | 858,242 |
Stockholders' equity | 1,887,678 | 1,666,776 |
$2,615,334 | $2,525,018 |
THE COOPER COMPANIES, INC. AND SUBSIDIARIES | ||||
Consolidated Condensed Statements of Income | ||||
(In thousands, except earnings per share amounts) | ||||
(Unaudited) | ||||
Three Months Ended | Nine Months Ended | |||
July 31, | July 31, | |||
2011 | 2010 | 2011 | 2010 | |
Net sales | $351,396 | $295,635 | $969,926 | $845,165 |
Cost of sales | 148,594 | 119,649 | 388,755 | 355,923 |
Gross profit | 202,802 | 175,986 | 581,171 | 489,242 |
Selling, general and administrative expense | 133,617 | 111,265 | 373,453 | 323,183 |
Research and development expense | 11,725 | 8,588 | 31,843 | 24,788 |
Restructuring costs | -- | 14 | -- | 424 |
Settlement of preexisting relationship | 6,080 | -- | -- | -- |
Amortization of intangibles | 5,493 | 4,723 | 14,940 | 13,439 |
Operating income | 45,887 | 51,396 | 160,935 | 127,408 |
Interest expense | 3,217 | 8,729 | 14,436 | 28,684 |
Loss on extinguishment of debt | -- | -- | 16,487 | -- |
Litigation settlement charge | -- | -- | -- | 27,000 |
Other income (expense), net | 386 | 985 | (128) | (1,174) |
Income before income taxes | 43,056 | 43,652 | 129,884 | 70,550 |
Provision for income taxes | 4,919 | 3,925 | 11,092 | 5,945 |
Net income | $38,137 | $39,727 | $118,792 | $64,605 |
Diluted earnings per share | $0.78 | $0.86 | $2.46 | $1.40 |
Number of shares used to compute earnings per share | 49,009 | 46,402 | 48,362 | 46,232 |
Soft Contact Lens Revenue Update
Worldwide Market vs.
The data below is extracted from a compilation of industry participants' revenue by the Contact Lens Institute (CLI), an independent market research firm. This data is compiled using gross product sales at foreign exchange rates set by CLI. It therefore excludes items such as discounts, rebates, currency hedges and freight reimbursements.
Worldwide Manufacturers' Soft Contact Lens Revenue | |||||||
(U.S. dollars in millions; constant currency; unaudited) | |||||||
Calendar 2Q11 | Trailing Twelve Months | ||||||
Market | CVI | Market | CVI | ||||
Market | Change | Change | Market | Change | Change | ||
Sales by Category | |||||||
Spheres | $ 1,324 | 3% | 10% | $ 5,182 | 4% | 8% | |
Torics | 323 | 8% | 10% | 1,249 | 9% | 14% | |
Multifocal | 82 | 5% | 1% | 314 | 10% | (1%) | |
WW Soft Contact Lenses | $ 1,729 | 4% | 9% | $ 6,745 | 5% | 9% | |
Sales by Modality | |||||||
Single Use | $ 650 | 8% | 12% | $ 2,473 | 8% | 10% | |
Other | 1,079 | 2% | 9% | 4,272 | 3% | 8% | |
WW Soft Contact Lenses | $ 1,729 | 4% | 9% | $ 6,745 | 5% | 9% | |
Sales by Material | |||||||
Hydrogel | $ 993 | (0%) | (2%) | $ 3,948 | (2%) | (4%) | |
Silicone Hydrogel | 736 | 11% | 47% | 2,797 | 16% | 60% | |
WW Soft Contact Lenses | $ 1,729 | 4% | 9% | $ 6,745 | 5% | 9% | |
Sales by Geography | |||||||
Americas | $ 662 | 6% | 7% | $ 2,562 | 6% | 9% | |
EMEA | 506 | 4% | 12% | 1,961 | 7% | 10% | |
Asia Pacific | 561 | 2% | 10% | 2,222 | 2% | 5% | |
WW Soft Contact Lenses | $ 1,729 | 4% | 9% | $ 6,745 | 5% | 9% | |
United States | $ 570 | 7% | 8% | $ 2,189 | 6% | 10% | |
International | 1,159 | 3% | 10% | 4,556 | 4% | 8% | |
WW Soft Contact Lenses | $ 1,729 | 4% | 9% | $ 6,745 | 5% | 9% |
COO-E
CONTACT:Source:Albert G. White, III VP, Investor Relations, Treasurer & Chief Strategic OfficerKim Duncan Director, Investor Relations ir@cooperco.com 925-460-3663 www.coopercos.com
News Provided by Acquire Media